Black Diamond Therapeutics (NASDAQ:BDTX) Shares Up 2.6%

Black Diamond Therapeutics, Inc. (NASDAQ:BDTXGet Free Report)’s stock price was up 2.6% during trading on Monday . The stock traded as high as $4.49 and last traded at $4.34. Approximately 774,289 shares were traded during mid-day trading, an increase of 34% from the average daily volume of 579,686 shares. The stock had previously closed at $4.23.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of Black Diamond Therapeutics in a report on Wednesday, November 22nd.

Read Our Latest Research Report on BDTX

Black Diamond Therapeutics Stock Performance

The stock has a market capitalization of $224.10 million, a price-to-earnings ratio of -2.04 and a beta of 2.59. The business has a 50-day moving average of $3.03 and a 200-day moving average of $2.87.

Hedge Funds Weigh In On Black Diamond Therapeutics

Hedge funds have recently made changes to their positions in the stock. Bank of Montreal Can purchased a new stake in Black Diamond Therapeutics during the second quarter worth about $76,000. Rock Springs Capital Management LP acquired a new stake in Black Diamond Therapeutics during the 2nd quarter worth approximately $2,844,000. Artal Group S.A. boosted its position in Black Diamond Therapeutics by 24.3% in the 2nd quarter. Artal Group S.A. now owns 2,046,517 shares of the company’s stock valued at $10,335,000 after buying an additional 400,000 shares during the period. Candriam S.C.A. acquired a new position in shares of Black Diamond Therapeutics in the second quarter worth $2,525,000. Finally, VR Adviser LLC acquired a new position in shares of Black Diamond Therapeutics in the second quarter worth $1,786,000.

About Black Diamond Therapeutics

(Get Free Report)

Black Diamond Therapeutics, Inc, a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial.

Further Reading

Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.